Aduro Biotech, Inc is a biotechnology business based in the US. Aduro Biotech shares (ADRO) are listed on the NASDAQ and all prices are listed in US Dollars. Aduro Biotech employs 69 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Aduro Biotech
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ADRO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- ADRO shares summary
- Compare share dealing platforms
- Is ADRO stock a buy or sell?
- Stock performance over time
- Can I short ADRO shares?
- Are ADRO shares over-valued?
- Aduro Biotech's financials
- How volatile are ADRO shares?
- Does Aduro Biotech pay a dividend?
- Have ADRO shares ever split?
- Other common questions
Aduro Biotech stock price (NASDAQ: ADRO)Use our graph to track the performance of ADRO stocks over time.
Aduro Biotech shares at a glance
|52-week range||$11.00 - $16.09|
|50-day moving average||$3.71|
|200-day moving average||$2.91|
|Wall St. target price||$18.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.15|
Buy Aduro Biotech shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aduro Biotech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Aduro Biotech under- or over-valued?
Valuing Aduro Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aduro Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aduro Biotech's PEG ratio
Aduro Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aduro Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Aduro Biotech financials
|Revenue TTM||$28 million|
|Gross profit TTM||$-48,610,000|
|Return on assets TTM||-13.9%|
|Return on equity TTM||-87.44%|
|Market capitalisation||$236.6 million|
TTM: trailing 12 months
Shorting Aduro Biotech shares
There are currently 3.2 million Aduro Biotech shares held short by investors – that's known as Aduro Biotech's "short interest". This figure is 2.7% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Aduro Biotech shares can be evaluated.
Aduro Biotech's "short interest ratio" (SIR)
Aduro Biotech's "short interest ratio" (SIR) is the quantity of Aduro Biotech shares currently shorted divided by the average quantity of Aduro Biotech shares traded daily (recently around 688870.17167382). Aduro Biotech's SIR currently stands at 4.66. In other words for every 100,000 Aduro Biotech shares traded daily on the market, roughly 4660 shares are currently held short.
However Aduro Biotech's short interest can also be evaluated against the total number of Aduro Biotech shares, or, against the total number of tradable Aduro Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aduro Biotech's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aduro Biotech shares in existence, roughly 40 shares are currently held short) or 0.0486% of the tradable shares (for every 100,000 tradable Aduro Biotech shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aduro Biotech.
Find out more about how you can short Aduro Biotech stock.
Aduro Biotech share dividends
We're not expecting Aduro Biotech to pay a dividend over the next 12 months.
Have Aduro Biotech's shares ever split?
Aduro Biotech's shares were split on a 1:5 basis on 1 October 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aduro Biotech shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Aduro Biotech shares which in turn could have impacted Aduro Biotech's share price.
Aduro Biotech share price volatility
Over the last 12 months, Aduro Biotech's shares have ranged in value from as little as $11 up to $16.094. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aduro Biotech's is 0.3861. This would suggest that Aduro Biotech's shares are less volatile than average (for this exchange).
Aduro Biotech overview
Aduro Biotech, Inc. , an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B. V.
Aduro Biotech in the news
Frequently asked questionsWhat percentage of Aduro Biotech is owned by insiders or institutions?
Currently 29.837% of Aduro Biotech shares are held by insiders and 44.755% by institutions. How many people work for Aduro Biotech?
Latest data suggests 69 work at Aduro Biotech. When does the fiscal year end for Aduro Biotech?
Aduro Biotech's fiscal year ends in December. Where is Aduro Biotech based?
Aduro Biotech's address is: 740 Heinz Avenue, Berkeley, CA, United States, 94710-2224 What is Aduro Biotech's ISIN number?
Aduro Biotech's international securities identification number is: US16961L1061 What is Aduro Biotech's CUSIP number?
Aduro Biotech's Committee on Uniform Securities Identification Procedures number is: 00739L101
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert